芦康沙妥珠单抗联合贝伐珠单抗治疗HER2－乳腺癌脑转移的临床观察 点击下载
| 论文标题： | 芦康沙妥珠单抗联合贝伐珠单抗治疗HER2－乳腺癌脑转移的临床观察 |
| 英文标题： | |
| 中文摘要： | 目的 观察芦康沙妥珠单抗联合贝伐珠单抗治疗人表皮生长因子受体2阴性（HER2－）乳腺癌脑转移患者的疗效与安全性。方法回顾性收集2024年12月至2025年11月南阳医学高等专科学校第一附属医院收治的90例HER2－乳腺癌脑转移患者资料，根据治疗方案的不同将患者分为对照组（55例）和试验组（35例）。试验组患者接受芦康沙妥珠单抗联合贝伐珠单抗治疗，对照组患者接受常规系统治疗，包括白蛋白结合型紫杉醇类方案、卡培他滨类方案、吉西他滨/长春瑞滨联合铂类方案。比较两组患者的近期疗效、无进展生存期（PFS）、脑转移相关疗效、不良反应发生情况、因不良反应停药及治疗相关死亡情况。结果试验组患者的客观缓解率（ORR）、疾病控制率、中位PFS、颅内病灶控制及神经系统症状改善比例均显著高于对照组（P＜0.05）；分层结果显示，试验组中乳腺癌脑转移特异性分级预后评分≥2.0分及＜2.0分患者的PFS均显著长于对照组（P＜0.05）。两组激素减量/停用患者比例、各级不良反应发生率、因不良反应停药发生率比较，差异均无统计学意义（P＞0.05）。两组均未出现与治疗相关的死亡患者。结论与常规系统治疗比较，芦康沙妥珠单抗联合贝伐珠单抗可显著提高HER2－乳腺癌脑转移患者的ORR，延长其PFS，且总体安全性可控。 |
| 英文摘要： | OBJECTIVE To evaluate the efficacy and safety of sacituzumab tirumotecan combined with bevacizumab for the treatment of human epidermal growth factor receptor 2-negative （HER2－） breast cancer with brain metastases.METHODS Clinical data of 90 patients with HER2－ breast cancer with brain metastases treated at the First Affiliated Hospital of Nanyang Medical College from December 2024 to November 2025 were retrospectively collected. According to the treatment regimens， the patients were divided into a control group （ n ＝55） and an experimental group （ n ＝35）. Patients in the experimental group received sacituzumab tirumotecan combined with bevacizumab， whereas those in the control group received conventional systemic therapy， including albumin-bound paclitaxel-based regimens， capecitabine-based regimens， or gemcitabine/vinorelbine combined with platinum-based regimens. Short-term efficacy， progression-free survival （PFS）， brain metastasis-related efficacy， adverse events， treatment discontinuation due to adverse events， and treatment-related deaths were compared between the two groups.RESULTS The objective response rate （ORR）， disease control rate， median PFS， intracranial disease control rate， and proportion of patients with improvement in neurological symptoms in the experimental group were significantly higher than in the control group （ P ＜0.05）. Stratified analysis showed that PFS of the experimental group was significantly longer than the control group among patients with Breast-Graded Prognostic Assessment scores ≥2.0 and ＜2.0 （ P ＜0.05）. There were no statistically significant differences in the proportion of patients with glucocorticoid dose reduction/discontinuation， the incidence of adverse events of different grades， or the rate of treatment discontinuation due to adverse events between the two groups （ P ＞0.05）. No treatment-related deaths occurred in either group.CONCLUSIONS Compared with conventional systemic therapy， sacituzumab tirumotecan combined with bevacizumab can improve the ORR and prolong PFS in patients with HER2－ breast cancer with brain metastases， with an overall manageable safety profile. |
| 期刊： | 2026年第37卷第16期 |
| 作者： | 杨玉凤；杨秀丽；程鹏；沈玲；杨倩；邵营波 |
| 英文作者： | YANG Yufeng，YANG Xiuli，CHENG Peng，SHEN Ling，YANG Qian，SHAO Yingbo |
| 关键字： | 乳腺癌；HER2阴性；脑转移；芦康沙妥珠单抗；贝伐珠单抗；疗效；安全性 |
| KEYWORDS： | Breast cancer;HER2－;brain metastases;sacituzumab tirumotecan;bevacizumab;Efficacy;Safety |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！